BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9717158)

  • 1. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract]   [Full Text] [Related]  

  • 2. [New quinolones for the treatment of community-acquired pneumonia--pro].
    Zimmerli S
    Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
    [No Abstract]   [Full Text] [Related]  

  • 3. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 4. [The place of the new quinolones in the guidelines on the treatment of community-acquired pneumonia].
    Dorca J
    Arch Bronconeumol; 1999 May; 35 Suppl 3():77-80. PubMed ID: 10410230
    [No Abstract]   [Full Text] [Related]  

  • 5. Newer fluoroquinolones and the management of respiratory tract infections.
    Karchmer AW
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S15. PubMed ID: 10984322
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical experience of levofloxacin in community acquired pneumonia].
    Arancibia F; Maldonado A; Torres A
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():14-8. PubMed ID: 10563105
    [No Abstract]   [Full Text] [Related]  

  • 7. [Alexander Project--5 years in Poland].
    Hryniewicz W
    Pol Merkur Lekarski; 2003 Jan; 14(79):5-8. PubMed ID: 12712818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical assessment of tosufloxacin tosilate.
    Kohno S
    J Infect Chemother; 2002 Mar; 8(1):19-27. PubMed ID: 11957115
    [No Abstract]   [Full Text] [Related]  

  • 9. Importance of atypical pathogens of community-acquired pneumonia.
    Plouffe JF
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug not considered a first-line agent.
    Lexchin J
    Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049
    [No Abstract]   [Full Text] [Related]  

  • 11. [The antibacterial therapy of community-acquired pneumonia].
    Khveshchuk PF; Rakov AL; Sinopal'nikov AI; Rudakova AV
    Voen Med Zh; 1999 Jan; 320(1):25-36. PubMed ID: 10200622
    [No Abstract]   [Full Text] [Related]  

  • 12. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
    Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
    Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
    Ball P
    Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
    Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
    Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-course beta-lactam treatment for community-acquired pneumonia.
    Stralin K; Sjöberg L; Holmberg H
    Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore.
    Chiang WC; Teoh OH; Chong CY; Goh A; Tang JP; Chay OM
    Respirology; 2007 Mar; 12(2):254-61. PubMed ID: 17298459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.